UBS initiated coverage of Cullinan Therapeutics (CGEM) with a Buy rating and $30 price target The firm launched coverage of SMID cap biotech sector with a focus in oncology and autoimmune diseases. Its top pick is Syndax. Cullinan has an innovative T cell engager “ready to disrupt” the multibillion dollar autoimmune market, the analyst tells investors in a research note.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGEM:
- Cullinan Management Advances SLE Treatment with FDA Trial
- Cullinan receives U.S. FDA clearance for IND application for CLN-978
- Cullinan Management Advances SLE Treatment with CLN-978 Trial
- 3 Best Stocks to Buy Now, 9/17/2024, According to Top Analysts
- Cullinan Therapeutics receives approval to initiate Phase 1 trial of CLN-978